Correlated expression levels of endothelin receptor B and Plexin C1 in melanoma.

Discussion concerning the effect of endothelin receptor B (Ednrb) on melanoma continues because Ednrb has been reported to have both tumor promoting and suppressive effects for melanoma. In order to examine Ednrb-related signaling in melanomagenesis, DNA microarray analysis for a melanoma from a RFP/RET-transgenic mouse (RET-mouse) and a melanoma from an Ednrb-heterozygously deleted RET-mouse [Ednrb(+/-);RET-mouse], in both of which melanoma spontaneously develops, was performed in this study. We found that the expression level of Plexin C1 (PlxnC1), a suppressor for melanoma, in a melanoma from an Ednrb(+/-);RET-mouse was drastically decreased compared to that in a melanoma from a RET-mouse. Therefore, we further examined the correlation between Ednrb and PlxnC1 expression levels in melanomas. PlxnC1 transcript expression levels in melanomas from Ednrb(+/-);RET-mice were lower than those in melanomas from RET-mice. A strong correlation between Ednrb and PlxnC1 transcript expression levels (R = 0.78, p < 0.01) was also found in melanomas from both RET-mice and Ednrb(+/-);RET-mice. Correspondingly, there was a significant correlation between transcript (R = 0.80; p < 0.01) and protein (R = 0.60; p < 0.01) expression levels of EDNRB and PLXNC1 in human primary melanomas. Together with our results showing that the expression level of PLXNC1 transcript was reduced in EDNRB-depleted human melanoma cells, our results showing positively correlated expression levels of Ednrb/EDNRB and PlxnC1/PLXNC1 in melanoma suggest that PlxnC1/PLXNC1 is involved in the Ednrb/EDNRB-mediated suppressive effect on melanoma.

[1]  N. Ohgami,et al.  L-cysteine as a regulator for arsenic-mediated cancer-promoting and anti-cancer effects. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[2]  T. Tsuzuki,et al.  c-Ret–mediated hearing loss in mice with Hirschsprung disease , 2010, Proceedings of the National Academy of Sciences.

[3]  Masahide Takahashi,et al.  CD109 expression levels in malignant melanoma. , 2010, Journal of dermatological science.

[4]  T. Tsuzuki,et al.  A novel mouse model for de novo Melanoma. , 2010, Cancer research.

[5]  P. Hersey,et al.  A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy , 2010, Molecular Cancer.

[6]  G. Scott,et al.  Plexin C1, a receptor for semaphorin 7a, inactivates cofilin and is a potential tumor suppressor for melanoma progression. , 2009, The Journal of investigative dermatology.

[7]  G. Scott,et al.  Semaphorin 7a promotes spreading and dendricity in human melanocytes through beta1-integrins. , 2008, The Journal of investigative dermatology.

[8]  M. Millward,et al.  A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma , 2005, Investigational New Drugs.

[9]  C. Lebbé,et al.  Association between endothelin receptor B nonsynonymous variants and melanoma risk. , 2005, Journal of the National Cancer Institute.

[10]  I. Stamenkovic,et al.  Endothelin Receptor B Inhibition Triggers Apoptosis and Enhances Angiogenesis in Melanomas , 2004, Cancer Research.

[11]  S. Tilghman,et al.  The temporal requirement for endothelin receptor-B signalling during neural crest development , 1999, Nature.

[12]  P. Patterson,et al.  An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.